HIV Seropositivity
65
2
5
40
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.2%
4 terminated out of 65 trials
90.9%
+4.4% vs benchmark
11%
7 trials in Phase 3/4
18%
7 of 40 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 40 completed trials
Clinical Trials (65)
Telehealth Delivery (Tele-B6)
Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention
Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
A Pilot Study of Metformin to Reduce Cerebrovascular Dysfunction in Participants With HIV and Metabolic Syndrome.
Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis
iTransition Development
Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV
Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen
Implementation of STTR Strategies Among People Who Inject Drugs in Malaysia
A Multilevel, Multiphase Optimization Strategy for PrEP (MOST:PrEP)
Collision of Three Global Pandemics: the Effect of Tuberculosis and HIV on the Epidemiological, Clinical, Virological and Immunological Trajectory of COVID-19 in Botswana and Namibia
Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients
Precariousness and Sexual Vulnerability of People From Haiti Living With or Without HIV in French Guiana
Immuno-virological Evaluation of Persons Living With HIV (PLWH)
Lower Urinary Tract Symptoms in Males Living With HIV
National Survey About Trajectory and Life Conditions of HIV Trans People in France